Bristol-Myers Squibb Co - Company Profile
Powered by 
All the data and insights you need on Bristol-Myers Squibb Co in one report.
$295
- Save hours of research time and resources with
our up-to-date Bristol-Myers Squibb Co Strategy Report
- Understand Bristol-Myers Squibb Co position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreBristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, immunology, cardiovascular, and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
Headquarters
United States of America
Address
Route 206 And Province Line Road, Princeton, New Jersey, 08543
Website
www.bms.com
Telephone
1 609 2524621
No of Employees
34,100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BMY (NYSE)
Revenue (2022)
$45.0B
-2.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
26.8%
(2022 vs 2021)
Market Cap*
$97.9B
Net Profit Margin (2022)
XYZ
30.1%
(2022 vs 2021)
* As of and is in US$
Bristol-Myers Squibb Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cardiovascular Drugs | Abecma |
| Diabetes Alliance Products | Abraxane |
| Virology Drugs | Azactam |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company received approval from the European Commission for Reblozyl (luspatercept) as a treatment for adults with transfusion-dependent anaemia. |
| 2024 | Regulatory Approval | In April, the company and 2seventy bio, Inc. received approval from the U.S. Food and Drug Administration for Abecma (idecabtagene vicleucel; ide-cel) to treat adult patients with myeloma. |
| 2024 | Acquisitions/Mergers/Takeovers | In March, the company acquired Karuna Therapeutics Inc. |
Competitor Comparison
| Key Parameters | Bristol-Myers Squibb Co | Johnson & Johnson | Merck & Co Inc | Sanofi | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | Switzerland |
| City | Princeton | New Brunswick | Kenilworth | Paris | Basel |
| State/Province | New Jersey | New Jersey | New Jersey | Ile-de-France | - |
| No. of Employees | 34,100 | 131,900 | 72,000 | 87,994 | 76,057 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher S. Boerner Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2024 | - |
| David V. Elkins | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 55 |
| Paul von Autenried | Executive Vice President; Chief Information Officer | Senior Management | 2019 | 60 |
| Greg Meyers | Chief Digital and Technology Officer; Executive Vice President | Senior Management | 2018 | 51 |
| Kim Jablonski | Executive Vice President; Chief Compliance Officer - Ethics Officer | Senior Management | 2023 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward